Propranolol in the treatment of ulcerated infantile hemangiomas: a clinical analysis of 18 cases

doi:10.19438/j.cjoms.2017.03.015

Abstract

Abstract: PURPOSE: To evaluate the clinical efficacy and safety of oral propranolol in the management of ulcerated infantile hemangiomas (IHs). METHODS: Oral propranolol was administered to 18 infants with hemangioma complicated by ulceration at a dose of 1-1.5 mg/kg of body weight per day. The treatment was continued for 3-12 months. Weekly visits were required until the ulcerations were healed, then changed to monthly visits. The therapeutic outcomes and safety were assessed by the changes of colors, size of tumor, healing of the ulcers and adverse effects throughout the course of treatment. RESULTS: Among 18 patients, ulcerations were healed within 2-7 weeks. The mean therapeutic duration was 8 months ranging from 3 to 12 months. Two of them left scars in the end of treatment. The main adverse effects were bradycardia, diarrhea, milk regurgitation, sleep disturbance, which resolved without special management. No major adverse effects were observed. CONCLUSIONS: Oral propranolol for ulcerated IHs can make the ulcer heal in a short time, and can significantly reduce hemangioma size; the adverse reactions were minimal.

Key words: Infantile hemangioma, Ulceration, Propranolol, Beta blocker

CLC Number:

R739.8

CHENG Mo-sha, ZHANG Kai-chi, WANG Xu-kai.. Propranolol in the treatment of ulcerated infantile hemangiomas: a clinical analysis of 18 cases[J]. China Journal of Oral and Maxillofacial Surgery, 2017, 15(3): 264-267.

References

[1] 中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组.口腔颌面部血管瘤治疗指南[J]. 中国口腔颌面外科杂志, 2011, 9(1): 61-67.
[2] Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature [J]. Pediatr Dermatol, 2008, 25(2): 168-173.
[3] 孙桦梁, 席善龙, 王绪凯, 等. 口服普萘洛尔治疗婴幼儿腮腺区血管瘤的疗效观察 [J]. 口腔颌面外科杂志, 2013, 23(6): 463-466.
[4] Wananukul S, Chatproedprai S. Ulcerated hemangiomas: clinical features and management [J]. J Med Assoc Thai, 2002, 85(11): 1220-1225.
[5] Shin HT, Orlow SJ, Chang MW. Ulcerated hemangioma of infancy: a retrospective review of 47 patients [J]. Br J Dermatol, 2007, 156(5): 1050-1052.
[6] 马刚, 林晓曦. 溃疡性血管瘤的研究进展 [J]. 组织工程与重建外科杂志, 2011, 7(6): 350-353.
[7] Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck [M]. New York: Wiley-liss Inc., 1999: 3, 57-58, 93-169.
[8] Li G, Xu DP, Cheng C, et al. Oral propranolol for parotid infantile hemangiomas[J]. J Craniofac Surg, 2015, 26(2): 438-440.
[9] Greene AK, Couto RA. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol [J]. Plast Reconstr Surg, 2011, 128(3): 743-752.
[10] Bauland CG, Lüning TH, Smit JM, et al. Untreated hemangiomas: growth pattern and residual lesions [J]. Plast Reconstr Surg, 2011, 127(4): 1643-1648.
[11] David LR, Malek MM, Argenta LC. Efficacy of pulse dye laser therapy for the treatment of ulcerated hemangiomas: a review of 78 patients [J]. Br J Plast Surg, 2003, 56(4): 317-327.
[12] Thomas RF, Hornung RL, Manning SC, et al. Hemangiomas of infancy: treatment of ulceration in the head and neck [J]. Arch Facial Plast Surg, 2005, 7(5): 312- 315.
[13] Chamlin SL, Haggstrom AN, Drolet BA, et al. Multicenter prospective study of ulcerated hemangiomas [J]. J Pediatr, 2007, 151(6): 684-689.
[14] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. N Engl J Med, 2008, 358(24): 2649-2651.
[15] Li G, Xu DP, Tong S, et al. Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions: a randomized clinical trial [J]. J Craniofac Surg, 2016, 27(1): 56-60.
[16] 宫贺, 徐大朋, 王绪凯, 等. 0.5%马来酸噻吗洛尔联合普萘洛尔治疗婴幼儿血管瘤的疗效分析[J]. 中国口腔颌面外科杂志, 2014, 12(5): 441- 445.
[17] Chisholm KM, Chang KW, Truong MT, et al. β-Adrenergic receptor expression in vascular tumors [J]. Mod Pathol, 2012, 25(11): 1446-1451.
[18] 薛雷. 血管瘤发病机制及治疗前景展望 [J]. 中国实用口腔科杂志, 2010, 3(10): 632- 635.